FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004456086> ?p ?o ?g. }

• W2004456086 endingPage "516" @default.
• W2004456086 startingPage "511" @default.
• W2004456086 abstract "We report the largest retrospective, phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic leukemia. Total number of patients was 103; median age was 65 years (range 39–85). Median number of prior lines of therapy was 4 (range 1–13), including, in most cases, rituximab-, fludarabine- and alemtuzumab-based regimens; 13 patients had been allografted. Of 113 adverse events, 28 (29%) were considered to be directly related to ofatumumab. Grade 3–4 toxicities included neutropenia (10%), thrombocytopenia (5%), anemia (3%), pneumonia (17%), and fever (3%). Two heavily pre-treated patients developed progressive multifocal leukoencephalopathy. On an intention-to-treat analysis, the overall response rate was 22% (3 complete response, 1 incomplete complete response). Median progression-free and overall survival times were 5 and 11 months, respectively. This study confirms in a daily-life setting the feasibility and acceptable toxicity of ofatumumab treatment in advanced chronic lymphocytic leukemia. The complete response rate, however, was low. Therefore, treatment with ofatumumab should be moved to earlier phases of the disease. Ideally, this should be done in combination with other agents, as recently approved for ofatumumab plus chlorambucil as front-line treatment for patients unfit for fludarabine. This study is registered at clinicaltrials.gov identifier:01453062." @default.
• W2004456086 created "2016-06-24" @default.
• W2004456086 creator A5002714921 @default.
• W2004456086 creator A5007139107 @default.
• W2004456086 creator A5015131529 @default.
• W2004456086 creator A5016119103 @default.
• W2004456086 creator A5019866348 @default.
• W2004456086 creator A5021513448 @default.
• W2004456086 creator A5025217094 @default.
• W2004456086 creator A5028727344 @default.
• W2004456086 creator A5030701526 @default.
• W2004456086 creator A5030806032 @default.
• W2004456086 creator A5036299617 @default.
• W2004456086 creator A5036988600 @default.
• W2004456086 creator A5039504007 @default.
• W2004456086 creator A5039819830 @default.
• W2004456086 creator A5042672780 @default.
• W2004456086 creator A5044130307 @default.
• W2004456086 creator A5047631289 @default.
• W2004456086 creator A5054193089 @default.
• W2004456086 creator A5054258973 @default.
• W2004456086 creator A5056554686 @default.
• W2004456086 creator A5056555162 @default.
• W2004456086 creator A5057853741 @default.
• W2004456086 creator A5058376349 @default.
• W2004456086 creator A5065902991 @default.
• W2004456086 creator A5068240503 @default.
• W2004456086 creator A5069046684 @default.
• W2004456086 creator A5070914643 @default.
• W2004456086 creator A5071015212 @default.
• W2004456086 creator A5074839524 @default.
• W2004456086 creator A5080861890 @default.
• W2004456086 creator A5081682713 @default.
• W2004456086 creator A5088476247 @default.
• W2004456086 creator A5089025495 @default.
• W2004456086 creator A5089632360 @default.
• W2004456086 creator A5090615083 @default.
• W2004456086 date "2015-01-16" @default.
• W2004456086 modified "2023-10-18" @default.
• W2004456086 title "Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia" @default.
• W2004456086 cites W1566121303 @default.
• W2004456086 cites W1593874097 @default.
• W2004456086 cites W1829212672 @default.
• W2004456086 cites W1974855794 @default.
• W2004456086 cites W2016973656 @default.
• W2004456086 cites W2017416510 @default.
• W2004456086 cites W2018967658 @default.
• W2004456086 cites W2020671967 @default.
• W2004456086 cites W2049353008 @default.
• W2004456086 cites W2053683902 @default.
• W2004456086 cites W2108206643 @default.
• W2004456086 cites W2108726442 @default.
• W2004456086 cites W2122725450 @default.
• W2004456086 cites W2124575836 @default.
• W2004456086 cites W2125134816 @default.
• W2004456086 cites W2139983745 @default.
• W2004456086 cites W2140606816 @default.
• W2004456086 cites W2141139539 @default.
• W2004456086 cites W2142099365 @default.
• W2004456086 cites W2161563262 @default.
• W2004456086 cites W2169386895 @default.
• W2004456086 cites W4238310152 @default.
• W2004456086 doi "https://doi.org/10.3324/haematol.2014.118158" @default.
• W2004456086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4380724" @default.
• W2004456086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25596264" @default.
• W2004456086 hasPublicationYear "2015" @default.
• W2004456086 type Work @default.
• W2004456086 sameAs 2004456086 @default.
• W2004456086 citedByCount "36" @default.
• W2004456086 countsByYear W20044560862015 @default.
• W2004456086 countsByYear W20044560862016 @default.
• W2004456086 countsByYear W20044560862017 @default.
• W2004456086 countsByYear W20044560862018 @default.
• W2004456086 countsByYear W20044560862019 @default.
• W2004456086 countsByYear W20044560862020 @default.
• W2004456086 countsByYear W20044560862021 @default.
• W2004456086 countsByYear W20044560862022 @default.
• W2004456086 crossrefType "journal-article" @default.
• W2004456086 hasAuthorship W2004456086A5002714921 @default.
• W2004456086 hasAuthorship W2004456086A5007139107 @default.
• W2004456086 hasAuthorship W2004456086A5015131529 @default.
• W2004456086 hasAuthorship W2004456086A5016119103 @default.
• W2004456086 hasAuthorship W2004456086A5019866348 @default.
• W2004456086 hasAuthorship W2004456086A5021513448 @default.
• W2004456086 hasAuthorship W2004456086A5025217094 @default.
• W2004456086 hasAuthorship W2004456086A5028727344 @default.
• W2004456086 hasAuthorship W2004456086A5030701526 @default.
• W2004456086 hasAuthorship W2004456086A5030806032 @default.
• W2004456086 hasAuthorship W2004456086A5036299617 @default.
• W2004456086 hasAuthorship W2004456086A5036988600 @default.
• W2004456086 hasAuthorship W2004456086A5039504007 @default.
• W2004456086 hasAuthorship W2004456086A5039819830 @default.
• W2004456086 hasAuthorship W2004456086A5042672780 @default.
• W2004456086 hasAuthorship W2004456086A5044130307 @default.
• W2004456086 hasAuthorship W2004456086A5047631289 @default.
• W2004456086 hasAuthorship W2004456086A5054193089 @default.
• W2004456086 hasAuthorship W2004456086A5054258973 @default.
• W2004456086 hasAuthorship W2004456086A5056554686 @default.

• next